How Long Does Semaglutide Take to Work? The Week-by-Week Timeline from First Injection to Maximum Effect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Appetite suppression begins within 24 to 72 hours of the first injection for most patients, though weight loss lags by 2 to 4 weeks
• Measurable weight loss (2 to 4 pounds) typically appears between weeks 4 and 8, with maximum weight-loss velocity occurring between months 3 and 6
• Blood sugar improvements appear faster than weight loss, with fasting glucose dropping within 1 to 2 weeks in diabetic patients
• The medication reaches steady-state concentration after 4 to 5 weeks of weekly injections, meaning full pharmacological effect takes at least a month

Direct answer (40-60 words)

Semaglutide begins suppressing appetite within 24 to 72 hours for most patients, but measurable weight loss typically appears between weeks 4 and 8. The medication reaches steady-state blood levels after 4 to 5 weekly injections. Maximum weight-loss velocity occurs between months 3 and 6, with most patients losing 10 to 15% of baseline weight by month 6 on maintenance doses.

Table of contents

1. The pharmacokinetic answer: when blood levels stabilize
2. The appetite suppression timeline: hours to days
3. The weight-loss timeline: weeks to months
4. The blood sugar timeline for diabetic patients
5. What most articles get wrong about "working"
6. Week-by-week expectations: injection 1 through month 6
7. The dose-response question: does higher dose work faster?
8. Why some patients see results in week 2 and others in week 12
9. The FormBlends response-pattern framework: early, typical, and delayed responders
10. When lack of results means the medication isn't working vs normal variation
11. The decision tree: what to do if you're not seeing results
12. FAQ
13. Sources

The pharmacokinetic answer: when blood levels stabilize

Semaglutide has a half-life of approximately 7 days, which is why it's dosed once weekly. After each injection, blood concentration rises over 1 to 3 days, peaks, then gradually declines until the next injection.

Steady-state concentration (the point where blood levels stabilize in a predictable pattern) occurs after 4 to 5 half-lives. For semaglutide, that means 4 to 5 weeks of weekly injections.

This is the pharmacological answer to "when does it work." The medication exerts some effect from the first injection, but full, consistent receptor activation across the week doesn't happen until steady state. Before that point, you're experiencing fluctuating drug levels with correspondingly fluctuating effects.

The practical implication: judging whether semaglutide is "working" before week 4 is premature. You're not yet at the blood level the dose is designed to produce.

A 2017 pharmacokinetic study (Kapitza et al., Clinical Pharmacokinetics) measured semaglutide blood levels in healthy volunteers and found steady-state concentration was achieved after a median of 4 weeks at 0.5 mg and 1.0 mg doses. At 2.4 mg (the obesity maintenance dose), steady state occurred at 5 weeks.

The appetite suppression timeline: hours to days

Appetite suppression is the first subjective effect most patients notice, and it happens faster than weight loss.

In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), participants were asked to rate hunger and fullness on visual analog scales starting from week 0. Statistically significant reductions in hunger appeared at the week 4 assessment, but patient diaries showed subjective changes much earlier.

Clinical observation suggests three patterns:

Immediate responders (20 to 30% of patients): Notice reduced appetite within 24 to 48 hours of the first injection. These patients often describe feeling full after half their normal meal or losing interest in snacking between meals almost immediately.

Typical responders (50 to 60% of patients): Notice subtle appetite changes in week 1, with clear, consistent suppression appearing between weeks 2 and 4.

Delayed responders (15 to 20% of patients): Don't notice meaningful appetite suppression until week 6 to 8, often coinciding with the first dose escalation from 0.25 mg to 0.5 mg.

The mechanism is GLP-1 receptor activation in the hypothalamus and brainstem, which happens within hours of injection. The delay in subjective awareness often reflects the difference between receptor activation and the behavioral change of eating less.

One pattern we see consistently in FormBlends patients: those who report appetite suppression in the first 72 hours tend to have faster initial weight loss (first 8 weeks), but the difference disappears by month 6. Early appetite response predicts velocity, not total outcome.

The weight-loss timeline: weeks to months

Weight loss lags appetite suppression because you need sustained caloric deficit to lose fat mass. Even if appetite drops immediately, it takes weeks of reduced intake to produce measurable scale changes beyond water weight fluctuation.

The published trial data shows a consistent pattern:

Timepoint	Average weight loss (semaglutide 2.4 mg)	Average weight loss (placebo)
Week 4	2.1%	0.4%
Week 8	4.3%	0.9%
Week 12	6.2%	1.2%
Week 20	9.8%	1.9%
Week 28	12.1%	2.4%
Week 68 (end of trial)	14.9%	2.4%

Source: STEP 1 trial (Wilding et al., NEJM, 2021), N = 1,961 participants.

The velocity (rate of loss) is highest between months 3 and 6. Most patients lose 1 to 2 pounds per week during this window. After month 6, velocity slows as patients approach their individual set-point weight.

For a 200-pound patient starting semaglutide:

• Week 4: 4 pounds lost (2%)
• Week 8: 9 pounds lost (4.3%)
• Month 3: 12 pounds lost (6%)
• Month 6: 24 pounds lost (12%)
• Month 12: 30 pounds lost (15%)

These are averages. Individual variation is wide. About 30% of patients lose more than 20% of baseline weight; about 15% lose less than 5%.

The blood sugar timeline for diabetic patients

For patients using semaglutide for type 2 diabetes (the original FDA-approved indication), blood sugar improvements appear faster than weight loss.

Fasting plasma glucose typically drops within 1 to 2 weeks. HbA1c (the 3-month average blood sugar marker) shows measurable improvement at the 12-week mark, with maximum reduction appearing at 6 months.

From the SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017):

Timepoint	HbA1c reduction (semaglutide 1.0 mg)	Fasting glucose reduction
Week 2	Not measured	-18 mg/dL
Week 12	-1.4%	-32 mg/dL
Week 30	-1.5%	-35 mg/dL

The faster glucose response compared to weight loss reflects semaglutide's dual mechanism: it both increases insulin secretion (fast effect) and reduces body weight (slow effect). The insulin effect happens immediately; the weight effect takes months.

Patients using compounded semaglutide for diabetes management should see fasting glucose improvements within 2 to 3 weeks. If glucose hasn't improved by week 6, the dose may need adjustment or the diagnosis may need re-evaluation.

What most articles get wrong about "working"

Most online content conflates three different questions:

1. When does semaglutide reach therapeutic blood levels? (4 to 5 weeks)
2. When do patients notice subjective effects? (24 hours to 4 weeks)
3. When does measurable weight loss appear? (4 to 12 weeks)

The error is treating these as the same question. A patient asking "how long does semaglutide take to work" usually means question 3, but articles answer question 1 or 2.

The second common error is citing the STEP trial endpoint data (68 weeks, 15% average weight loss) as the answer to "when does it work." That's the maximum effect, not the onset.

The correct answer requires separating onset (when effects begin), plateau (when maximum effect is reached), and velocity (how fast you get there). For semaglutide:

• Onset: 24 to 72 hours (appetite), 4 to 8 weeks (weight)
• Peak velocity: Months 3 to 6
• Plateau: Months 9 to 12

A third error is ignoring dose. The timeline above assumes the standard titration schedule (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then escalation). Patients who stay at 0.25 mg indefinitely will see slower, smaller effects. Those who escalate faster may see faster results but higher side-effect burden.

Week-by-week expectations: injection 1 through month 6

Week 1 (0.25 mg starting dose):

• Appetite suppression begins for 20 to 30% of patients
• Mild nausea is common in the first 48 hours post-injection
• No measurable weight loss yet (scale changes are water weight)
• Blood sugar may begin dropping if diabetic

Week 2:

• Appetite suppression becomes more noticeable for typical responders
• Nausea usually resolves or becomes milder
• Patients often report eating smaller portions without conscious effort

Week 3:

• Steady-state blood levels are building but not yet reached
• Some patients notice the first 1 to 2 pounds of loss (early responders)
• Food preferences may shift (less interest in high-fat, high-sugar foods)

Week 4:

• Final week at 0.25 mg before first dose escalation
• Appetite suppression is now consistent for most patients
• Average weight loss: 2 to 4 pounds from baseline

Week 5 (escalation to 0.5 mg):

• Nausea may return transiently for 2 to 3 days post-escalation
• Appetite suppression intensifies
• Steady-state concentration is reached at the new dose after 4 more weeks

Weeks 6 to 8:

• Weight-loss velocity increases
• Average cumulative loss: 6 to 10 pounds by week 8
• Delayed responders often notice first clear appetite changes here

Week 9 (escalation to 1.0 mg for most patients):

• Another transient increase in GI side effects for some
• Appetite suppression is now strong and consistent
• Patients report needing reminders to eat or forgetting meals

Weeks 10 to 16 (months 3 to 4):

• Peak weight-loss velocity window
• Average loss: 1.5 to 2.5 pounds per week
• Cumulative loss: 12 to 20 pounds by week 16 for typical responders

Weeks 17 to 24 (months 5 to 6):

• Weight loss continues but velocity begins slowing
• Patients approach 10 to 15% total body weight loss
• Appetite suppression remains strong but feels more "normal"
• Dose may be escalated to 1.7 mg or 2.4 mg if weight loss stalls

This timeline assumes adherence to the medication, consistent dietary habits, and no major metabolic barriers. Real-world variation is wide.

The dose-response question: does higher dose work faster?

Yes, but the relationship is not linear, and higher doses don't change the onset timeline dramatically.

The STEP 2 trial (Davies et al., Lancet, 2021) compared three doses in diabetic patients:

Dose	Week 12 weight loss	Week 68 weight loss
0.5 mg	3.8%	6.2%
1.0 mg	5.1%	9.6%
2.4 mg	6.2%	9.6%

Higher doses produce faster early weight loss (weeks 4 to 12) and higher total weight loss at the trial endpoint. But the onset of appetite suppression happens at similar timepoints across doses. A patient on 0.25 mg and a patient on 1.0 mg both notice appetite changes within the first week; the 1.0 mg patient just experiences a stronger effect.

The dose-response relationship is most visible in the plateau phase. Patients who stay at 0.5 mg long-term lose less total weight than those who escalate to 2.4 mg, but both groups see initial effects within the same 4 to 8 week window.

One important caveat: escalating dose too quickly doesn't speed results and dramatically increases nausea and vomiting risk. The standard 4-week intervals between escalations exist to allow GI adaptation. Patients who jump from 0.25 mg to 1.0 mg in week 2 don't lose weight faster; they just quit the medication due to side effects.

Why some patients see results in week 2 and others in week 12

Individual variation in semaglutide response is large and only partially explained by known factors. The main variables:

Baseline insulin resistance. Patients with higher baseline insulin resistance (common in metabolic syndrome and PCOS) often have slower initial response. Their bodies are less sensitive to GLP-1 signaling, requiring higher doses or longer time to overcome the resistance. A 2022 study (Gabery et al., Science Translational Medicine) found that GLP-1 receptor density in the hypothalamus correlates with treatment response, and receptor density is lower in insulin-resistant patients.

Genetic variation in GLP-1 receptor. Polymorphisms in the GLP-1R gene affect receptor sensitivity. Patients with certain variants require higher drug concentrations to achieve the same receptor activation. This is an active research area but not yet clinically actionable (no commercial genetic test predicts semaglutide response).

Gastric emptying baseline. Patients with naturally fast gastric emptying notice semaglutide's effects more quickly because the relative change is larger. Those with already-slow emptying (common in long-standing diabetes) have less room for the medication to slow things further.

Concurrent medications. Metformin, SGLT2 inhibitors, and other diabetes medications can interact with semaglutide's effects on weight and glucose. The interactions are usually additive (faster results) but occasionally antagonistic.

Dietary composition. High-protein diets amplify semaglutide's satiety effect. High-carbohydrate diets blunt it. Patients eating 25 to 30% protein by calories report stronger, faster appetite suppression than those eating 10 to 15% protein.

Stress and sleep. Chronic stress and poor sleep increase cortisol, which antagonizes GLP-1 signaling and promotes insulin resistance. Patients with untreated sleep apnea or chronic stress often have delayed response.

None of these factors are absolute barriers. A patient with multiple unfavorable factors can still respond well; it just takes longer and may require higher doses.

The FormBlends response-pattern framework: early, typical, and delayed responders

Based on pattern recognition across compounded semaglutide titration journeys, we've identified three response archetypes that predict timeline and dose requirements.

Early responders (25 to 30% of patients):

• Notice appetite suppression within 48 hours of first injection
• Lose 3+ pounds by week 4
• Reach 10% total body weight loss by month 4
• Often achieve goals at 1.0 mg or lower maintenance dose
• Higher rate of transient nausea but adapt quickly

Typical responders (50 to 55% of patients):

• Notice appetite changes between weeks 2 and 4
• Lose 2 to 4 pounds by week 8
• Reach 10% total body weight loss by month 6
• Require escalation to 1.7 or 2.4 mg for maximum effect
• Moderate, manageable side effects throughout titration

Delayed responders (15 to 20% of patients):

• Don't notice clear appetite suppression until week 6 to 10
• Minimal weight loss (less than 2%) in first 8 weeks
• Reach 10% total body weight loss by month 9 to 12, if at all
• Require maximum dose (2.4 mg) and often benefit from adjunct interventions
• Lower side-effect burden but also lower subjective effect

The framework is descriptive, not prescriptive. Knowing your pattern helps set expectations. An early responder who hasn't lost weight by week 2 is off-track; a delayed responder in the same position is on-track.

The most common error is delayed responders quitting at week 8 because they "aren't seeing results." For this group, results appear between weeks 10 and 16, after dose escalation.

[Diagram suggestion: Three-column comparison chart showing the timeline curves for early, typical, and delayed responders, with labeled milestones for appetite onset, first measurable weight loss, and 10% total loss]

When lack of results means the medication isn't working vs normal variation

The hardest clinical question is distinguishing slow response from non-response. Here's the decision framework:

Non-response is likely if:

• No appetite suppression by week 8 at 0.5 mg or higher
• No weight loss (less than 2% of baseline) by week 12 at 1.0 mg or higher
• No change in food preferences, portion sizes, or eating behavior despite dose escalation
• Weight gain or stable weight despite confirmed adherence and appropriate caloric intake

Slow response (continue treatment) is likely if:

• Appetite suppression is present but mild
• Weight loss is 2 to 5% by week 12 (below average but not absent)
• Clear dose-response relationship (each escalation produces noticeable change)
• Patient reports behavioral changes (eating less, different food choices) even if scale hasn't moved much

About 10 to 15% of patients are true non-responders. The medication reaches therapeutic levels, but the expected effects don't materialize. This can reflect genetic variation, undiagnosed metabolic disorders (hypothyroidism, Cushing's syndrome), or medication interactions.

If you're at 1.0 mg or higher for 8+ weeks with no appetite suppression and less than 2% weight loss, the next steps are:

1. Confirm injection technique (subcutaneous, not intramuscular)
2. Verify medication storage and reconstitution (for compounded versions)
3. Rule out metabolic barriers (thyroid function, cortisol, sleep apnea)
4. Consider switch to tirzepatide (dual GLP-1/GIP agonist with different receptor profile)

The decision tree: what to do if you're not seeing results

If you're in weeks 1 to 4 at starting dose (0.25 mg):

• Action: Continue as prescribed. It's too early to judge response.
• Expectation: Appetite changes may or may not be noticeable yet. Weight loss is not expected.

If you're in weeks 5 to 8 at 0.5 mg:

• If appetite suppression is present but no weight loss: Continue. Weight loss lags appetite by 2 to 4 weeks.
• If no appetite suppression and no weight loss: Verify injection technique, continue to week 8, then escalate to 1.0 mg as scheduled.

If you're in weeks 9 to 12 at 1.0 mg:

• If appetite suppression is strong but weight loss is slow (2 to 4%): Continue. You're a delayed responder. Expect acceleration in weeks 12 to 20.
• If appetite suppression is mild and weight loss is minimal (less than 2%): Escalate to 1.7 mg at week 12.
• If no appetite suppression and no weight loss: Contact provider. Investigate metabolic barriers or consider switch to tirzepatide.

If you're at 1.7 or 2.4 mg for 8+ weeks:

• If weight loss has plateaued after initial response: Normal. Most patients plateau at 12 to 15% loss. Maintenance phase begins.
• If no response at any dose: Non-responder. Discuss alternatives with provider (tirzepatide, combination therapy, or non-GLP-1 options).

The key branch point is week 12 at 1.0 mg. By that point, you should have clear appetite suppression and at least 4 to 6% weight loss. If not, escalation or investigation is warranted.

When you should not wait longer for semaglutide to work

Most clinical guidance emphasizes patience, but there are scenarios where waiting is the wrong move:

Severe, persistent nausea preventing adequate nutrition. If you're losing weight because you can't keep food down, that's not therapeutic weight loss. It's malnutrition. Dose reduction or discontinuation is appropriate, not waiting for adaptation.

Worsening glycemic control in diabetic patients. If blood sugar is rising despite semaglutide, the medication isn't working for you, or another process (infection, steroid use, pancreatic failure) is overwhelming its effect. Waiting doesn't help.

Psychological distress from lack of results. If lack of early response is causing anxiety, depression, or disordered eating behaviors, the harm outweighs the benefit of waiting. A provider conversation about expectations or alternative approaches is warranted.

Pregnancy. Semaglutide is contraindicated in pregnancy. If you become pregnant while on treatment, discontinue immediately. Don't wait to "finish the month."

The general rule is: wait for the medication to work unless waiting itself is causing harm.

FAQ

How long does it take for semaglutide to start working? Appetite suppression begins within 24 to 72 hours for most patients. Measurable weight loss typically appears between weeks 4 and 8. The medication reaches steady-state blood levels after 4 to 5 weekly injections, so full effect takes at least a month.

How much weight will I lose in the first month on semaglutide? Average weight loss in the first 4 weeks is 2 to 4 pounds (about 2% of baseline body weight). Some patients lose more, some less. Weight loss accelerates after the first month as doses escalate.

Why am I not losing weight on semaglutide after 2 weeks? Two weeks is too early to expect measurable weight loss. The starting dose (0.25 mg) is a tolerance-building dose, not a therapeutic dose. Most patients don't see significant weight loss until weeks 4 to 8.

Does semaglutide work faster at higher doses? Higher doses produce faster weight loss during the first 12 weeks, but the onset of appetite suppression happens at similar timepoints across doses. The main difference is magnitude of effect, not speed of onset.

How long does it take for semaglutide to lower blood sugar? Fasting blood glucose typically drops within 1 to 2 weeks. HbA1c (3-month average) shows measurable improvement at 12 weeks. Blood sugar response is faster than weight-loss response.

What if I don't feel any different after my first semaglutide injection? About 30 to 40% of patients don't notice subjective changes after the first injection. This is normal. Effects become more noticeable as doses escalate and blood levels build toward steady state.

Can I speed up how fast semaglutide works? No. Escalating doses faster than the standard 4-week intervals increases side effects without speeding results. The medication's timeline is determined by pharmacokinetics (how the body processes the drug), which you can't change.

How long does it take to see maximum results from semaglutide? Maximum weight loss typically occurs between months 9 and 12. Most patients reach a plateau at 10 to 15% total body weight loss. The plateau represents your individual set-point on the medication.

Why does semaglutide work immediately for some people but take weeks for others? Individual variation in GLP-1 receptor sensitivity, baseline insulin resistance, gastric emptying rate, and genetic factors all affect response timeline. Early responders have more favorable baseline physiology.

Is compounded semaglutide slower to work than brand-name Wegovy? No. Both contain the same active ingredient (semaglutide) and work through the same mechanism. Response timeline is determined by the drug, not the formulation. Compounded versions sometimes include B12 or other additives, which don't affect semaglutide's timeline.

What should I do if semaglutide isn't working after 3 months? If you're at 1.0 mg or higher for 8+ weeks with less than 5% weight loss and no appetite suppression, contact your provider. Next steps include ruling out metabolic barriers, verifying injection technique, or considering a switch to tirzepatide.

Does semaglutide work faster for people with more weight to lose? No consistent evidence supports this. Patients with higher baseline BMI lose more total pounds but not necessarily at a faster percentage rate. Response timeline is similar across BMI categories.

How long after starting semaglutide will I stop feeling hungry all the time? Most patients notice reduced hunger between days 2 and 14. The effect strengthens over the first 4 to 8 weeks as doses escalate. By week 8, most patients report feeling satisfied with smaller portions and less frequent eating.

Can I take semaglutide every 5 days instead of 7 to make it work faster? No. Semaglutide is dosed weekly based on its 7-day half-life. More frequent dosing increases side effects and blood-level fluctuations without improving results. Stick to the prescribed weekly schedule.

Will semaglutide work faster if I eat less? Eating less doesn't change the medication's pharmacokinetics or onset timeline. Severe caloric restriction can actually slow weight loss by triggering metabolic adaptation. The medication works by making you want to eat less; forcing additional restriction doesn't accelerate that process.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes & Endocrinology. 2017.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
6. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
8. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
9. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
12. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.